We are live on
!
Find out more
VAM
Visium Asset Management Portfolio holdings
AUM
$1.43B
1-Year Est. Return
3.58%
This Fund
S&P 500
This Quarter
Est. Return
+4.67%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.05B
AUM Growth
+$276M
(+4.1%)
Cap. Flow
+$73M
Cap. Flow
% of AUM
1.04%
Top 10 Holdings %
Top 10 Hldgs %
27.96%
Holding
1,430
New
433
Increased
334
Reduced
305
Closed
319
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$182M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$170M |
| 3 |
AET
Aetna Inc
AET
|
+$131M |
| 4 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$108M |
| 5 |
Brookdale Senior Living
BKD
|
+$91.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$435M |
| 2 |
Elevance Health
ELV
|
+$121M |
| 3 |
Cigna
CI
|
+$119M |
| 4 |
WMGI
Wright Medical Group Inc
WMGI
|
+$82.7M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$72.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.34% |
| 2 | Financials | 7.86% |
| 3 | Consumer Discretionary | 7.17% |
| 4 | Technology | 6.32% |
| 5 | Industrials | 4.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOBE
151
DELISTED
Bob Evans Farms, Inc.
BOBE
| $10.1M | 0.14% |
197,196
-29,732
| -13% | -$1.38M |
|
152
Cabot Corp
CBT
$4.54B
| $10M | 0.14% |
269,097
+13,296
| +5% | +$574K |
|
|
VIRX
153
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $10M | 0.14% |
15,833
+1,547
| +11% | +$822K |
|
154
Mohawk Industries
MHK
$7.5B
| $9.98M | 0.14% |
52,296
+16,496
| +46% | +$3.05M |
|
155
MetLife
MET
$61.9B
| $9.9M | 0.14% |
+198,338
| New | +$9.39M |
|
156
Lear
LEA
$6.54B
| $9.88M | 0.14% |
88,000
-87,896
| -50% | -$10.1M |
|
|
MLNX
157
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $9.86M | 0.14% |
+202,922
| New | +$9.84M |
|
|
GRFS
158
Grifois
GRFS
$5.36B
| $9.86M | 0.14% |
636,440
-889,348
| -58% | -$14.4M |
|
159
Lipocine
LPCN
$17.5M
| $9.75M | 0.14% |
66,824
-4,117
| -6% | -$511K |
|
160
Ameriprise Financial
AMP
$48.3B
| $9.7M | 0.14% |
77,594
-70,313
| -48% | -$8.96M |
|
161
DuPont de Nemours
DD
$18.5B
| $9.7M | 0.14% |
74,809
+31,128
| +71% | +$4.03M |
|
|
FOE
162
DELISTED
Ferro Corporation
FOE
| $9.66M | 0.14% |
575,530
-156,277
| -21% | -$2.26M |
|
|
PFNX
163
DELISTED
Pfenex Inc.
PFNX
| $9.65M | 0.14% |
497,320
-10,200
| -2% | -$171K |
|
164
Home Depot
HD
$331B
| $9.52M | 0.13% |
85,630
+46,987
| +122% | +$5.26M |
|
165
Molson Coors Class B
TAP
$7.79B
| $9.35M | 0.13% |
+133,958
| New | +$9.96M |
|
|
KING
166
DELISTED
KING DIGITAL ENTMT PLC ORD SHS (IRL)
KING
| $9.33M | 0.13% |
654,842
-480,020
| -42% | -$7.44M |
|
167
Unum
UNM
$13.6B
| $9.32M | 0.13% |
260,746
-48,295
| -16% | -$1.69M |
|
168
Reliance Steel & Aluminium
RS
$20.7B
| $9.21M | 0.13% |
152,289
+2,887
| +2% | +$183K |
|
169
Norfolk Southern
NSC
$75.4B
| $9.15M | 0.13% |
104,720
+84,020
| +406% | +$8.19M |
|
170
TransDigm Group
TDG
$70.2B
| $9.1M | 0.13% |
40,509
+10,409
| +35% | +$2.33M |
|
171
Dollar Tree
DLTR
$24.4B
| $8.91M | 0.13% |
112,806
-220,659
| -66% | -$17.4M |
|
172
Stryker
SYK
$125B
| $8.81M | 0.12% |
92,222
-25,527
| -22% | -$2.42M |
|
173
Globus Medical
GMED
$10.7B
| $8.81M | 0.12% |
343,037
-6,157
| -2% | -$156K |
|
174
TG Therapeutics
TGTX
$7.96B
| $8.79M | 0.12% |
530,000
-771,500
| -59% | -$12.2M |
|
175
Globalstar
GSAT
$10.7B
| $8.7M | 0.12% |
274,851
+41,386
| +18% | +$1.61M |
|
Similar funds
FBNAT
CPS
LH
CPM
VFS
ZA
FVFIGP
WA
Visium Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, Visium Asset Management held 1,430 positions worth $7.05B, up 4.1% from $6.78B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Visium Asset Management's Q2 2015 filing shows 433 new, 334 increased, 305 reduced and 319 closed positions. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 635,000 shares worth $104M. The largest sale was Allergan plc, an estimated $435M.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 49% a quarter earlier, followed by Financials and Consumer Discretionary.
- Visium Asset Management's largest Q2 2015 buy was Sio Gene Therapies Inc. Common Stock: 635,000 shares worth $104M.
- Visium Asset Management added most to Bausch Health in Q2 2015, an estimated $182M increase.
- Visium Asset Management's biggest Q2 2015 reduction was Elevance Health, cutting an estimated $121M.
- Visium Asset Management fully exited Allergan plc in Q2 2015, selling an estimated $435M.
- Visium Asset Management's ten largest holdings make up 28% of its $7.05B portfolio in Q2 2015.
- Visium Asset Management opened 433 new positions and closed 319 in Q2 2015.
- Visium Asset Management's portfolio value rose 4.1% quarter-over-quarter to $7.05B.
Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.